Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04693715 · ClinicalTrials.gov registry record · Phase 2
Safety of RNS60 in Large Vessel Occlusion Stroke Patients Undergoing Endovascular Thrombectomy
A Phase 2 study, sponsored by Revalesio Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 83
- Enrollment target
NCT04693715 is a Phase 2 study that has completed, run by Revalesio Corporation. The registered enrollment target is 83 participants.
The verdict
NCT04693715, a Phase 2 study, has completed, sponsored by Revalesio Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 83 participants
- Enrollment target
Study Summary
A Phase II, randomized, blinded, placebo-controlled, parallel group study with patients experiencing a large vessel occlusion acute ischemic stroke who are selected for endovascular revascularization. Participants will be given a 48 h infusion of either 0.5 mL/kg/h RNS60 (up to a maximum of 65 mL/h), 1.0 mL/kg/h RNS60 (up to a maximum of 130 mL/h), or 1.0 mL/kg/h (up to a maximum of 130 mL/h) placebo (normal saline) starting within 30 minutes of consent after confirmation of candidacy for endovascular thrombectomy.
Interventions
- DRUG Placebo
- DRUG RNS60
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2021-07-07 |
| Est. Completion | 2023-11-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04693715
The ClinicalTrials.gov registry entry for NCT04693715 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Revalesio Corporation, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04693715 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04693715 about?
NCT04693715 is a clinical study titled "Safety of RNS60 in Large Vessel Occlusion Stroke Patients Undergoing Endovascular Thrombectomy". A Phase II, randomized, blinded, placebo-controlled, parallel group study with patients experiencing a large vessel occlusion acute ischemic stroke who are selected for endovascular revascularization. Participants will be given a 48 h infusion of either 0.5 mL/kg/h RNS60 (up to a maximum of 65 mL/h)...
What is the current status of trial NCT04693715?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 83 participants. The study started on 2021-07-07. Estimated completion is 2023-11-08.
What interventions are being tested in trial NCT04693715?
The interventions under investigation include: Placebo (DRUG), RNS60 (DRUG).
Who is sponsoring clinical trial NCT04693715?
This trial is sponsored by Revalesio Corporation, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.